Gabather AB was founded in 2014, based on 10 years research at Lund University, to develop novel drug candidates for the treatment of several diseases originating in the central nervous system (CNS). Since there are several areas of unmet need as well as many medicines going off-patent, it is an opportune moment to develop new drugs targeting the CNS area.
We focus on four main areas: Anti-psychotics, Anti-depressants and anxiolytics, analgesics, as well as conginition-enhancing treatments, including Alzheimer’s.
Many blockbuster drugs within our four focus areas are going off-patent, or are about to. This means generic copies are pushing down the revenues for major pharmaceutical companies, which creates a demand for novel treatments. Our drug candidates show promising development and are patented on several markets.
We have more than 10 years research at both Lund University and Research Institute of Biological Psychiatry in Roskilde as basis for our development projects.